Brook, M., Hennessy, C., Hester, J., Hammad, S., Alzhrani, A., Rombach, I., . . . Issa, F. (2024). Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation. Wolters Kluwer.
Chicago Style (17th ed.) CitationBrook, MO, et al. Late Treatment with Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation. Wolters Kluwer, 2024.
MLA (9th ed.) CitationBrook, MO, et al. Late Treatment with Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation. Wolters Kluwer, 2024.